Corteva (NYSE:CTVA) Stock Price Target Cut by Citigroup

Key Points

• Citigroup cut its Corteva price target from $13.65 to $10.30, maintaining a Neutral rating; the new target implied 9.4% upside from the reported share price of $9.41.
• Other analysts also lowered targets, including UBS to $10, while several maintained neutral or positive ratings. MarketBeat reported a consensus rating of Moderate Buy.
• Recent company pressures include Brazilian inventory overhang and pricing weakness; Corteva lowered its 2026 adjusted EPS outlook to $0.76–$0.80, below the cited $1.07 consensus estimate.

Corteva (NYSE:CTVA - Get Free Report) had its price target dropped by stock analysts at Citigroup from $13.65 to $10.30 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "neutral" rating on the stock. Citigroup's price target indicates a potential upside of 9.40% from the company's current price.

Other equities analysts have also recently issued research reports about the company. Argus reiterated a "buy" rating and set a $91.00 price target on shares of Corteva in a report on Friday, September 18th. BMO Capital Markets set a $15.00 price objective on Corteva in a research note on Friday, October 2nd. Mizuho set a $16.00 price objective on Corteva in a research report on Thursday. UBS Group cut their price objective on Corteva from $15.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday. Finally, Weiss Ratings downgraded Corteva from a "hold (c+)" rating to a "hold (c)" rating in a research note on Monday, August 3rd. Fifteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $52.60.

Corteva Stock Performance

Shares of CTVA traded up $0.23 during midday trading on Friday, reaching $9.41. The stock had a trading volume of 27,975,143 shares, compared to its average volume of 8,337,318. The firm has a market cap of $6.28 billion, a PE ratio of 6.24, a P/E/G ratio of 1.69 and a beta of 0.58. The firm has a 50 day simple moving average of $38.81 and a 200-day simple moving average of $69.88. Corteva has a one year low of $9.01 and a one year high of $90.97. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.07.

Institutional Investors Weigh In On Corteva

Several hedge funds have recently bought and sold shares of CTVA. State Board of Administration of Florida Retirement System increased its holdings in shares of Corteva by 7.6% during the third quarter. State Board of Administration of Florida Retirement System now owns 626,690 shares of the company's stock worth $48,662,000 after buying an additional 44,445 shares in the last quarter. Mosaic Family Wealth Partners LLC bought a new stake in Corteva during the 3rd quarter worth $204,000. Xcelsior Advisor Partners LLC grew its position in Corteva by 26.6% during the 3rd quarter. Xcelsior Advisor Partners LLC now owns 24,281 shares of the company's stock worth $1,885,000 after acquiring an additional 5,107 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in Corteva by 12.5% in the 3rd quarter. Bleakley Financial Group LLC now owns 18,309 shares of the company's stock worth $1,422,000 after purchasing an additional 2,032 shares in the last quarter. Finally, N.F.U. MUTUAL UNIT MANAGERS Ltd acquired a new position in Corteva in the 3rd quarter worth about $1,325,000. 81.54% of the stock is currently owned by institutional investors and hedge funds.

Corteva News Summary

These are some of the CTVA news items that stood out recently:

• Neutral Sentiment: JPMorgan cut its price target to $16 but kept an Overweight rating; RBC lowered its target to $11 while retaining Outperform. UBS cut its target to $10 and maintained Neutral, reflecting a more cautious view. JPMorgan analyst ratings
• Negative Sentiment: Brazilian inventory overhang and pricing pressure weighed on results, and management lowered 2026 adjusted EPS guidance to $0.76–$0.80 from a consensus estimate of $1.07. Revenue also fell 8.7% year over year, adding to investor concern about the duration of the downturn. Reuters: Corteva shares slide after Brazil weakness prompts forecast cut
• Negative Sentiment: Several analysts lowered their targets, including UBS to $10 and RBC to $11. Although the ratings were not downgraded, the target reductions underscore diminished expectations following the outlook cut. UBS analyst ratings

Corteva Company Profile

Corteva, Inc. is an agricultural science company that develops and supplies products and services for farmers. Its business focuses on seeds and crop protection, including technologies intended to help improve crop performance and manage weeds, insects, and plant diseases. Its seed portfolio includes corn, soybean, and other crop varieties, sold under brands such as Pioneer and Brevant. Corteva's crop protection offerings include herbicides, insecticides, fungicides, and biological products, alongside digital tools and services that support farm decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.